ADC Therapeutics SA (ADCT)
1.285
-0.02
(-1.15%)
USD |
NYSE |
Sep 09, 14:56
ADC Therapeutics Shareholders Equity (Quarterly) : -228.20M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -228.20M |
| March 31, 2026 | -216.38M |
| December 31, 2025 | -185.83M |
| September 30, 2025 | -238.18M |
| June 30, 2025 | -199.18M |
| March 31, 2025 | -238.22M |
| December 31, 2024 | -202.64M |
| September 30, 2024 | -171.95M |
| June 30, 2024 | -131.67M |
| March 31, 2024 | -194.45M |
| December 31, 2023 | -148.25M |
| September 30, 2023 | -54.18M |
| June 30, 2023 | -8.589M |
| Date | Value |
|---|---|
| March 31, 2023 | 37.68M |
| December 31, 2022 | 79.45M |
| September 30, 2022 | 104.78M |
| June 30, 2022 | 115.35M |
| March 31, 2022 | 162.67M |
| December 31, 2021 | 166.09M |
| September 30, 2021 | 187.31M |
| June 30, 2021 | 243.92M |
| March 31, 2021 | 297.97M |
| December 31, 2020 | 335.50M |
| September 30, 2020 | 376.06M |
| June 30, 2020 | 196.30M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| BeOne Medicines Ltd. | 5.174B |
| AC Immune SA | 43.60M |
| CRISPR Therapeutics AG | 1.747B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 279.38M |
| Total Liabilities (Quarterly) | 507.58M |
| Debt to Equity Ratio | -0.5152 |
| Current Ratio | 3.031 |
| Net Debt Paydown Yield | 49.76% |